Cargando…

High Expression of miR-34a Associated with Less Aggressive Cancer Biology but Not with Survival in Breast Cancer

Most breast cancer (BC) patients succumb to metastatic disease. MiR-34a is a well-known tumor suppressive microRNA which exerts its anti-cancer functions by playing a role in p53, apoptosis induction, and epithelial-mesenchymal transition (EMT) suppression. Molecular Taxonomy of Breast Cancer Intern...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tokumaru, Yoshihisa, Katsuta, Eriko, Oshi, Masanori, Sporn, Judith C., Yan, Li, Le, Lan, Matsuhashi, Nobuhisa, Futamura, Manabu, Akao, Yukihiro, Yoshida, Kazuhiro, Takabe, Kazuaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246662/ https://www.ncbi.nlm.nih.gov/pubmed/32357442 http://dx.doi.org/10.3390/ijms21093045

Ejemplares similares

Intratumoral Adipocyte-High Breast Cancer Enrich for Metastatic and Inflammation-Related Pathways but Associated with Less Cancer Cell Proliferation
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

Low expression of miR-29a is associated with aggressive biology and worse survival in gastric cancer
por: Tokumaru, Yoshihisa, et al.
Publicado: (2021)

High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

Organoids Are Limited in Modeling the Colon Adenoma–Carcinoma Sequence
por: Tokumaru, Yoshihisa, et al.
Publicado: (2021)

M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells
por: Tajirika, Toshihiro, et al.
Publicado: (2018)

Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase
por: Tokumaru, Yoshihisa, et al.
Publicado: (2019)

MiR‐133b inhibits growth of human gastric cancer cells by silencing pyruvate kinase muscle‐splicer polypyrimidine tract‐binding protein 1
por: Sugiyama, Taro, et al.
Publicado: (2016)

Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival
por: Okano, Maiko, et al.
Publicado: (2019)

Should we target “intermediate expression” of HER2 in older estrogen receptor positive patients?
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer
por: Oshi, Masanori, et al.
Publicado: (2022)

Altered Expression of Secreted Mediator Genes That Mediate Aggressive Breast Cancer Metastasis to Distant Organs
por: Maiti, Aparna, et al.
Publicado: (2021)

MYC Targets Scores Are Associated with Cancer Aggressiveness and Poor Survival in ER-Positive Primary and Metastatic Breast Cancer
por: Schulze, Amy, et al.
Publicado: (2020)

Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients
por: Oshi, Masanori, et al.
Publicado: (2020)

High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Annexin A1 Expression Is Associated with Epithelial–Mesenchymal Transition (EMT), Cell Proliferation, Prognosis, and Drug Response in Pancreatic Cancer
por: Oshi, Masanori, et al.
Publicado: (2021)

Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2021)

Intra-Tumoral Angiogenesis Is Associated with Inflammation, Immune Reaction and Metastatic Recurrence in Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Plasmacytoid Dendritic Cell (pDC) Infiltration Correlate with Tumor Infiltrating Lymphocytes, Cancer Immunity, and Better Survival in Triple Negative Breast Cancer (TNBC) More Strongly than Conventional Dendritic Cell (cDC)
por: Oshi, Masanori, et al.
Publicado: (2020)

Abundance of Microvascular Endothelial Cells Is Associated with Response to Chemotherapy and Prognosis in Colorectal Cancer
por: Oshi, Masanori, et al.
Publicado: (2021)

Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival
por: Oshi, Masanori, et al.
Publicado: (2021)

G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Transcriptomic Profile of Lymphovascular Invasion, a Known Risk Factor of Pancreatic Ductal Adenocarcinoma Metastasis
por: Takahashi, Hideo, et al.
Publicado: (2020)

NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation
por: Wu, Rongrong, et al.
Publicado: (2022)

A Novel Four-Gene Score to Predict Pathologically Complete (R0) Resection and Survival in Pancreatic Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

High G2M Pathway Score Pancreatic Cancer is Associated with Worse Survival, Particularly after Margin-Positive (R1 or R2) Resection
por: Oshi, Masanori, et al.
Publicado: (2020)

A Novel 4-gene Score to Predict Survival, Distant Metastasis and Response to Neoadjuvant Therapy in Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Urine as a Source of Liquid Biopsy for Cancer
por: Oshi, Masanori, et al.
Publicado: (2021)

Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment
por: Takeshita, Takashi, et al.
Publicado: (2022)

Biologically Aggressive Phenotype and Anti-cancer Immunity Counterbalance in Breast Cancer with High Mutation Rate
por: Takahashi, Hideo, et al.
Publicado: (2020)

Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Enhanced DNA Repair Pathway is Associated with Cell Proliferation and Worse Survival in Hepatocellular Carcinoma (HCC)
por: Oshi, Masanori, et al.
Publicado: (2021)

Postoperative changes in plasma miR21‐5p as a novel biomarker for colorectal cancer recurrence: A prospective study
por: Fukada, Masahiro, et al.
Publicado: (2021)

Tumor Tissue MIR92a and Plasma MIRs21 and 29a as Predictive Biomarkers Associated with Clinicopathological Features and Surgical Resection in a Prospective Study on Colorectal Cancer Patients
por: Fukada, Masahiro, et al.
Publicado: (2020)

The mode of progressive disease affects the prognosis of patients with metastatic breast cancer
por: Mori, Ryutaro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_inlgtit9le0l906bfga2q8e321